Search Bar & Filters
Found 393 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.
Actively Recruiting
Researchers are evaluating remibrutinib, an oral medication, in a Phase III clinical trial involving adolescents and adults aged 12 to 65 with IgE-mediated allergies to peanut, cows milk cooked and uncooked, or hens egg cooked and uncooked. The study compares remibrutinib to a placebo to assess its safety and effectiveness in managing these food allergies. Participants are divided into four sub-studies based on their specific allergy peanut, milk, egg, or a combination of these allergens. During the initial treatment period, participants receive either remibrutinib or placebo for up to 24 weeks in the first three sub-studies, and up to 4 weeks in the fourth sub-study. After this, all participants enter an open-label phase where they receive remibrutinib until Week 52. Following this period, eligible participants can join a separate open-label post-trial study to evaluate long-term effects, while others enter a 4-week safety follow-up without treatment. Throughout the study, participants undergo regular assessments including allergen challenges to measure tolerance to specific amounts of allergen proteins at Weeks 4 and 24, depending on the sub-study. Safety is monitored by recording any adverse events up to 56 weeks. Participants are asked to avoid exposure to their allergens and complete skin prick tests, blood tests for allergen-specific IgE, and double-blind placebo-controlled food challenges. The trial duration is 52 weeks with additional follow-up for some participants.
Actively Recruiting
Researchers are evaluating the use of delgocitinib cream applied twice daily to treat adults with mild to severe lichen sclerosus LS, focusing mainly on female participants since LS is more common in females. This Phase 3 trial is designed to assess the efficacy and safety of delgocitinib in comparison to a cream vehicle over a long period. The study includes two parts Part 1 enrolls females to determine the best dose, and Part 2 enrolls both males and females to further evaluate safety and efficacy. Participants will be assigned randomly to receive either delgocitinib cream at specified doses or a cream vehicle. Treatments are applied twice daily during an initial 12-week period followed by a continuation treatment period lasting 40 weeks. Various dosing regimens are used across groups, including delgocitinib cream alone, cream vehicle alone, or combinations transitioning between the two during the study. Male participants will be included in a substudy to evaluate delgocitinibs effects in men. During the trial, participants will attend clinic visits and undergo assessments including measurement of skin condition severity using the IGA-LS score, clinical lichen sclerosus score CLISSCO, and patient-reported scales for skin pain and itch. Quality of life related to vulvar symptoms will also be monitored. Safety is carefully tracked through adverse event reporting and laboratory tests throughout the study, which lasts from 55 to 60 weeks per participant. The primary outcome is the number of participants achieving a specific improvement in LS severity at week 12.
Actively Recruiting
Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects the eye and vision. This trial aims to compare a new medicine called tiespectus also known as MK-8748 or EYE201 with the standard treatment aflibercept to see if tiespectus works as well for people with NVAMD. The study is a randomized, double-masked, pivotal phase 23 trial focusing on treatment effectiveness and safety. Participants will be assigned to one of three groups one receiving a low dose of tiespectus, another receiving a high dose of tiespectus, and a third group receiving aflibercept. In the tiespectus groups, participants will get three initial injections every four weeks, followed by injections every eight weeks until week 48. After week 48, treatment intervals will be personalized based on individual responses, continuing up to week 92. The aflibercept group also receives three initial injections followed by injections every eight weeks until week 92. Throughout the study, participants will have their vision assessed using a standard eye chart to measure changes in best-corrected visual acuity BCVA from the start through one year. Additional measures include eye imaging to assess retinal thickness and monitoring for any side effects or adverse events up to approximately 96 weeks. The trial will last until June 2028, with ongoing monitoring and follow-up visits to evaluate the safety and effectiveness of the treatments.
Actively Recruiting
Researchers are studying the safety and effectiveness of a drug called tacabrutideg for people with B-cell malignancies, a type of cancer that affects white blood cells. These cancers include various forms such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and others. The study aims to find the best dose of tacabrutideg and evaluate how well it works in shrinking or eliminating these cancers. The study has two parts first, a dose escalation phase where different doses of tacabrutideg are tested to find a recommended dose that is safe and tolerable. Then, an expansion phase enrolls more participants to further assess the safety and effectiveness of the selected dose or doses. Tacabrutideg is given orally. The study includes multiple groups of participants with different types of B-cell malignancies, including some specific cohorts like Japanese participants and those who have not previously received certain kinase inhibitors. Participants will visit clinics regularly over about three years for treatment, health checks, blood tests, tumor imaging, and other assessments. Researchers will monitor side effects, measure cancer response, and collect blood samples to study how the drug behaves in the body. The main outcomes include safety, identifying the best dose, and overall cancer response rates. The study is open label, so both participants and doctors know the treatment given.
Actively Recruiting
Researchers are evaluating the effects of intravitreal remigromig EYE103 in adults with neovascular age-related macular degeneration NVAMD or macular edema following branch retinal vein occlusion BRVO. This randomized, dose-masked Phase 2 study includes four patient groups, comparing low and high doses of remigromig, alone or combined with aflibercept for certain participants. The study aims to assess safety and efficacy of these treatments for these eye conditions. Participants will receive three injections of remigromig into the study eye, spaced four weeks apart. In one group of incomplete responders with NVAMD, aflibercept injections are also given on the first day. Participants are randomized within four cohorts to receive either a low or high dose of remigromig, with some receiving combination therapy. Enrollment and treatment timing are managed by the study sponsor. Throughout the study, participants will return for safety and efficacy assessments at each injection visit and may have additional visits two weeks after injections depending on their group. Assessments include vision tests using the ETDRS chart, eye examinations, and imaging to measure retinal thickness. The main outcome measure is the change in best-corrected visual acuity at 12 weeks. The study concludes with a final visit at week 12, after which safety and effectiveness data will be reviewed.
Actively Recruiting
Researchers are conducting a master protocol study called IIBD to evaluate the safety and effectiveness of new treatments for adults with moderately to severely active ulcerative colitis or Crohns disease. This phase 2, randomized, controlled study includes multiple individual sub-studies that share key design features. Participants are assigned to the appropriate sub-study before being randomized to a treatment group, with the overall study lasting at least 62 weeks. The study treatments include mirikizumab given intravenously IV during the first study period. Responders then receive mirikizumab subcutaneously SC in the second period. Another group will receive oral LY4395089 combined with IV mirikizumab initially, then responders stop LY4395089 and continue with mirikizumab SC. These two treatment approaches are being assessed in parallel groups. Participants will undergo screening to confirm diagnosis and disease activity, followed by regular study visits during the treatment periods. Researchers will monitor laboratory test results and evaluate response to treatment using measures such as the modified Mayo score for ulcerative colitis and the Crohns disease activity index. The primary outcome includes tracking the number of participants assigned to each treatment group up to day 42. The study runs through March 2028 with ongoing safety and efficacy assessments.
Actively Recruiting
Researchers are conducting a Phase 2 clinical trial to create a framework for evaluating the safety and effectiveness of multiple investigational treatments for chronic weight management in adults with obesity or overweight. This master protocol includes intervention-specific appendices ISAs that allow for independent evaluation of different treatments as they become available. Participants may receive various drugs, including LY3305677, LY3841136, tirzepatide, LY3549492, macupatide, eloralintide, or placebo. These treatments are administered either subcutaneously or orally, with each ISA detailing specific intervention plans. The study uses a randomized, double-blind, parallel design to assess these interventions. Participants will be involved in screening and treatment phases, with safety and efficacy monitored throughout. The primary outcome measures the number of participants allocated to each ISA from baseline to week 6. The study is sponsored by Eli Lilly and Company and plans to complete by February 2028, enrolling adults aged 18 to 75 years with obesity or overweight under controlled conditions.
Actively Recruiting
Researchers are evaluating DCC-3009, an oral drug, for its safety, tolerability, and effectiveness in treating Gastrointestinal Stromal Tumor GIST. This Phase 12 master protocol study uses a modular design where each module tests DCC-3009 alone or with other anticancer therapies. The study includes dose escalation and dose expansion phases to explore different doses and effects. Participants receive DCC-3009 in 28-day treatment cycles. Module A includes a Part 1 dose escalation phase to determine safe dosing, followed by a Part 2 dose expansion phase to further study the drugs effects. The estimated treatment duration for participants is up to 2 years. During the study, participants will be closely monitored for dose-limiting toxicities and tumor response using imaging and clinical assessments. Researchers will measure outcomes such as objective response rate, duration of response, progression-free survival, overall survival, and drug concentration in the blood. Safety and treatment effects will be assessed over an estimated 24 months of follow-up.
Actively Recruiting
Researchers are evaluating two different weekly doses of Alpha1-Proteinase Inhibitor Alpha1-PI given by injection under the skin compared with the standard intravenous doses in adults with Alpha-1 Antitrypsin Deficiency. This Phase 3, open-label study aims to understand how the body processes the medicine and to assess the safety and tolerability of the different doses. Participants are randomly assigned to treatment groups in a parallel design, with both doctors and participants aware of the assigned treatment. Participants undergo two treatment periods the first with intravenous IV Liquid Alpha1-PI given weekly at either 60 mgkg or 120 mgkg for 8 weeks, followed by a second period with subcutaneous SC Alpha1-PI 15% injection at corresponding higher doses 90 mgkg or 180 mgkg also given weekly for 8 weeks. Participants receive each dosing schedule sequentially to compare pharmacokinetics and safety between IV and SC administration. During the study, participants have regular visits to monitor steady-state levels of Alpha1-PI in the blood, lung function tests, and safety assessments. Key measurements include the area under the curve AUC of Alpha1-PI over each weekly interval and trough serum levels at specific weeks. The study includes screening, 16 weeks of treatment divided into two 8-week periods, and ongoing safety and tolerability evaluations throughout.
1-10 of 393
1